CLVS Clovis Oncology Inc.

14.77
0  0%
Previous Close 14.77
Open
Price To Book 10.47
Market Cap 782,881,561
Shares 53,004,845
Volume 13,718
Short Ratio
Av. Daily Volume 1,454,459

NewsSee all news

  1. AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use
  2. See what the IHS Markit Score report has to say about Clovis Oncology Inc.
  3. Is Clovis Oncology Inc (CLVS) A Good Stock To Buy?
  4. The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix
  5. Clovis Oncology Names Ginger L. Graham as New Board of Directors Chair

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 ongoing. Abstract presented at ASCO June 2018.
Opdivo and Rubraca
Castration-resistant prostate cancer (mCRPC)
Phase 3 trial planned.
Opdivo and Rubraca
Triple-negative breast cancers
Phase 3 enrolment has commenced - noted August 8, 2018.
Opdivo and Rubraca ATHENA
Ovarian Cancer - First-line maintenance treatment
Phase 3 trial open for enrollment - February 22, 2017.
Rucaparib - TRITON3
Castration-Resistant Prostate Cancer
Phase 1b/2 trial initiated January 2016
Rociletinib in combination with atezolizumab
EGFR-mutant non-small cell lung cancer
Approval announced April 6, 2018.
Rucaparib ARIEL3
Ovarian cancer patients with a BRCA-like mutation
PDUFA date was June 28, 2016. Company expect CRL. Phase 3 TIGER-3 also terminated.
Rociletinib
Mutant EGFR T790M-positive lung cancer
Development discontinued
Lucitanib
Breast cancer
Approved December 19, 2016. Original PDUFA date under priority review was February 23, 2017.
Rucaparib ARIEL2
Cancer - ovarian second line
Phase 2 data to be presented fall 2019.
Rucaparib - TRITON2
Castrate-resistant prostate cancer (mCRPC)
Phase 2 trial to be discontinued due to lack of efficacy - April 12, 2019.
Rucaparib - ATLAS
Urothelial carcinoma
ESMO presentation at ESMO October 2018.
Lucitanib
HR+ Her2- metastatic breast cancer
Phase 3 confirmatory trial is enrolling.
Rucaparib ARIEL4
Relapsed ovarian cancer patients with BRCA mutations
Phase 2 data presented at AACR April 2019. PFS 9.1 months.
Rucaparib
Platinum-sensitive pancreatic cancer

Latest News

  1. AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use
  2. See what the IHS Markit Score report has to say about Clovis Oncology Inc.
  3. Is Clovis Oncology Inc (CLVS) A Good Stock To Buy?
  4. The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix
  5. Clovis Oncology Names Ginger L. Graham as New Board of Directors Chair
  6. Why Is Clovis (CLVS) Down 25.3% Since Last Earnings Report?
  7. Expanded Rubraca® (Rucaparib) Data from Clovis Oncology’s ARIEL3 and TRITON2 Trials in Ovarian and Prostate Cancers to be Presented at 2019 ASCO Annual Meeting
  8. Biotech Stocks Clobbered As Two Slammed With Sell Ratings
  9. Clovis Oncology Stock Sinks on Dim View of Cancer Drug Sales
  10. Clovis Oncology Presents Patient-Centered Outcomes Data from Phase 3 ARIEL3 Study for Rubraca®▼ in Advanced Ovarian Cancer
  11. Clovis Oncology Announces Presentations at 2019 ASCO Annual Meeting
  12. Edited Transcript of CLVS earnings conference call or presentation 7-May-19 12:30pm GMT
  13. Clovis (CLVS) Q1 Earnings Top Estimates, Rubraca Sales Strong
  14. Clovis Oncology (CLVS) Q1 2019 Earnings Call Transcript
  15. Clovis Oncology (CLVS) Reports Q1 Loss, Tops Revenue Estimates
  16. Clovis: 1Q Earnings Snapshot
  17. Clovis Oncology Announces First Quarter 2019 Operating Results